Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-01-20 Sale | 2026-01-22 5:34 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 20,000 | $26.75 | $535,099 | 745,188 (Indirect) | View |
| 2026-01-20 Sale | 2026-01-22 5:33 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,230 | $26.75 | $32,902 | 173,095 (Indirect Direct) | View |
| 2026-01-09 Sale | 2026-01-13 5:54 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 48,300 | $27.99 | $1,351,762 | 215,011 (Indirect) | View |
| 2026-01-08 Sale | 2026-01-12 5:12 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 132,500 | $26.23 | $3,476,014 | 765,188 (Indirect) | View |
| 2026-01-08 Sale | 2026-01-12 5:11 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 13,920 | $25.02 | $348,281 | 148,780 (Indirect Direct) | View |
| 2025-12-19 Sale | 2025-12-23 6:45 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 5,000 | $16.84 | $84,206 | 897,688 (Indirect) | View |
| 2025-12-08 Sale | 2025-12-10 5:13 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,663 | $21.02 | $140,073 | 263,311 (Indirect) | View |
| 2025-11-19 Sale | 2025-11-21 5:28 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $22.33 | $279,155 | 902,688 (Indirect) | View |
| 2025-11-17 Sale | 2025-11-19 6:45 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $21.82 | $272,739 | 890,392 (Indirect) | View |
| 2025-11-07 Sale | 2025-11-12 5:34 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $17.4 | $116,034 | 269,974 (Indirect) | View |
| 2025-10-20 Sale | 2025-10-22 7:20 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $22.08 | $276,025 | 915,188 (Indirect) | View |
| 2025-10-17 Sale | 2025-10-21 6:13 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $21.33 | $266,654 | 902,892 (Indirect) | View |
| 2025-10-07 Sale | 2025-10-09 5:21 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $20.1 | $133,993 | 276,641 (Indirect) | View |
| 2025-09-29 Sale | 2025-10-01 4:46 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.4 | $66,291 | 128,056 (Direct) | View |
| 2025-09-26 Sale | 2025-09-30 5:53 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 4,000 | $20.25 | $81,005 | 927,688 (Indirect) | View |
| 2025-09-26 Sale | 2025-09-30 5:51 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 3,700 | $20.06 | $74,228 | 915,392 (Indirect) | View |
| 2025-09-23 Sale | 2025-09-25 7:44 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 1,500 | $20.03 | $30,045 | 931,688 (Indirect) | View |
| 2025-09-23 Sale | 2025-09-25 7:42 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 2,800 | $20.03 | $56,084 | 919,092 (Indirect) | View |
| 2025-09-19 Sale | 2025-09-23 5:14 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 7,000 | $19.39 | $135,697 | 933,188 (Indirect) | View |
| 2025-09-17 Sale | 2025-09-19 7:12 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 6,000 | $19.29 | $115,723 | 921,892 (Indirect) | View |
| 2025-09-08 Sale | 2025-09-10 8:12 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $20.24 | $134,957 | 283,308 (Indirect) | View |
| 2025-08-27 Sale | 2025-08-29 5:03 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.63 | $67,039 | 131,306 (Direct) | View |
| 2025-08-20 Sale(A) | 2025-08-21 6:48 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 1,517 | $20 | $30,343 | 927,892 (Indirect) | View |
| 2025-08-19 Sale | 2025-08-21 6:46 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $19.86 | $248,217 | 940,188 (Indirect) | View |
| 2025-08-18 Sale | 2025-08-20 4:36 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 10,983 | $20.02 | $219,906 | 929,409 (Indirect) | View |
| 2025-08-07 Sale | 2025-08-11 6:51 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $18.24 | $121,616 | 289,975 (Indirect) | View |
| 2025-07-28 Sale | 2025-07-30 5:57 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.46 | $66,504 | 134,556 (Direct) | View |
| 2025-07-21 Sale | 2025-07-23 6:52 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $22.29 | $278,646 | 952,688 (Indirect) | View |
| 2025-07-17 Sale | 2025-07-21 7:21 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $22.52 | $281,518 | 940,392 (Indirect) | View |
| 2025-07-10 Sale | 2025-07-14 5:07 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $22.66 | $22,655 | 137,806 (Direct) | View |
| 2025-07-07 Sale | 2025-07-09 7:29 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $19.79 | $131,951 | 296,642 (Indirect) | View |
| 2025-06-27 Sale | 2025-07-01 4:42 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.91 | $67,956 | 138,806 (Direct) | View |
| 2025-06-20 Sale | 2025-06-24 5:36 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $21.4 | $267,458 | 965,188 (Indirect) | View |
| 2025-06-17 Sale | 2025-06-18 6:22 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $22.18 | $277,292 | 952,892 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-01-07 Option Award | 2026-01-09 6:10 pm | N/A 2036-01-07 | Enliven Therapeutics Inc. | ELVN | Garland J. Scott Director | 59,372 | $0 | 59,372 (Direct) | View |
Ownership | 2026-01-09 6:04 pm | N/A 2034-09-26 | Enliven Therapeutics Inc. | ELVN | Garland J. Scott Director | 0 | $0 | 26,580 (Direct) | View |
| 2025-12-22 Exercise | 2025-12-23 6:47 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 13,000 | $2.48 | 128,056 (Direct) | View |
| 2025-12-22 Exercise | 2025-12-23 6:47 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 13,000 | $0 | 128,056 (Direct) | View |
| 2025-12-17 Exercise | 2025-12-19 5:58 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 15,958 | $1.12 | 65,625 (Direct) | View |
| 2025-12-17 Exercise | 2025-12-19 5:58 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 15,958 | $0 | 65,625 (Direct) | View |
| 2025-12-11 Option Award | 2025-12-12 6:31 pm | N/A 2035-12-11 | Enliven Therapeutics Inc. | ELVN | Fair Richard A. PRESIDENT AND CEO | 875,000 | $0 | 875,000 (Direct) | View |
| 2025-09-29 Exercise | 2025-10-01 4:46 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 128,056 (Direct) | View |
| 2025-09-29 Exercise | 2025-10-01 4:46 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 128,056 (Direct) | View |
| 2025-08-27 Exercise | 2025-08-29 5:03 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 131,306 (Direct) | View |
| 2025-08-27 Exercise | 2025-08-29 5:03 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 131,306 (Direct) | View |
| 2025-07-28 Exercise | 2025-07-30 5:57 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 134,556 (Direct) | View |
| 2025-07-28 Exercise | 2025-07-30 5:57 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 134,556 (Direct) | View |
| 2025-07-10 Exercise | 2025-07-14 5:07 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $2.48 | 137,806 (Direct) | View |
| 2025-07-10 Exercise | 2025-07-14 5:07 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $0 | 137,806 (Direct) | View |
| 2025-06-27 Exercise | 2025-07-01 4:42 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 138,806 (Direct) | View |
| 2025-06-27 Exercise | 2025-07-01 4:42 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 138,806 (Direct) | View |